The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > September 2, 2025
Daily News
September 2, 2025
- Pharma Groups Press Pricing Reform at First Public-Private WG Meeting
September 2, 2025
- Fuji, Nitto Strike Sales Deal for Eylea Biosimilar, Eye November Listing
September 2, 2025
- Shionogi Completes Full Takeover of Torii under JT Deal
September 2, 2025
- Clinical Trial Environment Must Match Global Standards, Says JPMA Evaluation Chief
September 2, 2025
- Teva Takeda Renamed as T’s Pharma
September 2, 2025
- FDA Clears Leqembi Autoinjector; Launch Set for Oct. 6
September 2, 2025
- Santen’s Glaucoma Drug Tapcom Launched in China
September 2, 2025
- Takeda Wins Japan Approval for Takhzyro Pen Formulation
September 2, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…